Shenzhen Salubris Pharmaceuticals Co., Ltd.
SHZ: 002294.SZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Jie Yan
- Employees
- 3,596
- Headquarters
- Shenzhen, China
- IPO year
- 2009
- Market cap
- CN¥53.4B
- Website
- https://www.salubris.com
Loading 002294…
Loading profile data…Frequently asked questions about 002294
What does Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) do?
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel b...
Where does 002294.SZ trade?
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) trades on the Shenzhen Stock Exchange.
What sector is 002294.SZ in?
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) operates in the Healthcare sector, specifically in the Medical - Instruments & Supplies industry.
Who is the CEO of Shenzhen Salubris Pharmaceuticals Co., Ltd.?
Jie Yan is the chief executive officer of Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ).
Where is Shenzhen Salubris Pharmaceuticals Co., Ltd. headquartered?
Shenzhen Salubris Pharmaceuticals Co., Ltd. is headquartered in China.
Does 002294.SZ pay a dividend?
Yes — Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) paid a trailing twelve-month dividend of CNY 0.50 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 002294.SZ go public?
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) completed its initial public offering in 2009.